Show simple item record

 
dc.contributorDepartament de Salut
dc.contributor.authorCiruela-Navas, Pilar
dc.contributor.authorBroner, Sònia
dc.contributor.authorIzquierdo, Conchita
dc.contributor.authorPallarés, Roman
dc.contributor.authorMuñoz-Almagro, Carmen
dc.contributor.authorHernández-Baeza, Sergi
dc.contributor.authorGrau, Imma
dc.contributor.authorDomínguez-García, Àngela
dc.contributor.authorJané-Checa, Mireia
dc.contributor.authorThe Catalan Working Group on Invasive Pneumococcal Disease
dc.date.accessioned2020-01-29T12:18:41Z
dc.date.available2020-01-29T12:18:41Z
dc.date.issued2019-09
dc.identifier.citationCiruela P, Broner S, Izquierdo C, Pallarés R, Muñoz-Almagro C, Hernández S, et al. Indirect effects of paediatric conjugate vaccines on invasive pneumococcal disease in older adults. Int J Infect Dis. 2019 Sep;86:122-130.
dc.identifier.issn1201-9712
dc.identifier.urihttp://hdl.handle.net/11351/4569
dc.descriptionStreptococcus pneumoniae; IPD; PCV13; Adults; Case fatality rate; Comorbidities; Mortality
dc.description.abstractObjectives The aim of this study was to assess the indirect effect of paediatric 13-valent pneumococcal conjugate vaccine (PCV13) vaccination on people ≥65 years of age with invasive pneumococcal disease (IPD) in Catalonia and to determine factors predictive of mortality. Methods During 2014–2016, 1285 IPD cases were reported to the Public Health Agency of Catalonia. The indirect effect of paediatric PCV13 vaccination was calculated by comparing the incidence rate (IR) in 2016 (PCV13 year) with that in 2009 (pre-PCV13). Predictors of mortality were determined using multivariate logistic regression. Results Comparing 2016 and 2009, IPD decreased by 19% (IR 40.1 and 32.5 per 100 000 person-years, respectively). PCV13 serotypes decreased by 57% (IR 23.7 and 10.1), while non-PCV13 serotypes increased by 36% (IR 16.4 and 22.4). During 2014–2016, the mortality rate was 17.5%, and mortality was associated with age ≥85 years (adjusted odds ratio (aOR) 2.91, 95% confidence interval (CI) 1.89, 4.48), meningitis (aOR 2.29, 95% CI 1.25, 4.19), non-focal bacteraemia (aOR 3.73, 95% CI 2.00, 6.94), and ≥1 high-risk condition (aOR 1.89, 95% CI 1.08, 3.32). PPV23non13 serotypes were associated with lower mortality than PCV13 serotypes (aOR 0.54, 95% CI 0.34, 0.86). Conclusions The incidence of IPD in people ≥65 years of age decreased after the introduction of paediatric PCV13, and this was due to a reduction in PCV13 serotypes, although an increase in non-PCV13 serotypes was observed. Mortality was associated with age, meningitis, non-focal bacteraemia, ≥1 high-risk condition, and PCV13 serotypes.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesInternational journal of infectious diseases;86
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectPneumococs
dc.subjectVacuna antipneumocòccica
dc.subjectPersones grans
dc.subject.meshStreptococcus pneumoniae
dc.subject.meshPneumococcal Vaccines
dc.subject.meshAged
dc.titleIndirect effects of paediatric conjugate vaccines on invasive pneumococcal disease in older adults
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doihttps://doi.org/10.1016/j.ijid.2019.06.030
dc.subject.decsStreptococcus pneumoniae
dc.subject.decsvacunas antineumocócicas
dc.subject.decsanciano
dc.relation.publishversionhttps://www.ijidonline.com/article/S1201-9712(19)30275-9/fulltext
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Ciruela P, Jané M] Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Barcelona, Spain. CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain. [Broner S, Izquierdo C, Hernández S] Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Barcelona, Spain. [Pallarés R, Grau I] Hospital Universitari Bellvitge, Universitat de Barcelona (UB), L’Hospitalet, Spain. CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain. [Muñoz-Almagro C] CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain. Hospital Universitari Sant Joan de Déu, Esplugues, Spain. Department of Medicine, Universitat Internacional de Catalunya (UIC), Sant Cugat del Vallès, Spain. [Domínguez A] CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain. Departament de Medicina, Universitat de Barcelona (UB), Barcelona, Spain
dc.identifier.pmid31283992
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record